Abstract
BackgroundWe examined preoperative kinesin II-associated protein (KAP1), TIMP metallopeptidase inhibitor 1 (TIMP1) and stanniocalcin 2 (STC2) expression levels in patients with gastric cancers to assess their clinical application for diagnosing and monitoring diseases.MethodsReal-time reverse transcription-polymerase chain reaction was used to detect the expression levels of KAP1, TIMP1, STC2, talin 2 (TLN2), sushi-repeat-containing protein, X-linked 2 (SRPX2) and secreted protein, acidic, cysteine-rich (SPARC) in the patients’ peripheral blood karyocytes. The data were analyzed with receiver operating characteristics (ROC) curves.ResultsA total of 112 patients with gastric cancer, 42 patients with recurrence and 107 healthy volunteers were recruited. There were significant correlations between KAP1, TIMP1 and STC2 levels, and TNM tumor stages and distant metastases. The area under the ROC curves (AUC) of KAP1 was 0.803 ± 0.040 (P = 0.0001), the AUC of TIMP1 was 0.767 ± 0.043 (P = 0.0001) and the AUC of STC2 was 0.769 ± 0.045 (P = 0.0001), thus differentiating preoperative gastric cancer patients from healthy volunteers by ROC curve analysis. The AUC of STC2 was 0.739 ± 0.070 (P = 0.004) and the AUC of KAP1 was 0.418 ± 0.088 (P = 0.319), thus differentiating recurrence of gastric cancer from healthy volunteers by ROC curve analysis. High TIMP1 and STC2 expression levels were suspected to be poor prognostic factors of disease recurrence in patients with gastric cancer.ConclusionsKAP1, TIMP1 and STC2 expression levels may be potential biomarkers for the screening, diagnosis, prognosis and surveillance of gastric cancer.
Highlights
We examined preoperative kinesin II-associated protein (KAP1), tissue inhibitor of metalloproteases (TIMP) metallopeptidase inhibitor 1 (TIMP1) and stanniocalcin 2 (STC2) expression levels in patients with gastric cancers to assess their clinical application for diagnosing and monitoring diseases
The diagnostic efficacy of Kinesin II-associated protein (KAP1), TIMP metallopeptidase inhibitor 1 (TIMP1), STC2, talin 2 (TLN2), SRPX2 and SPARC in patients with gastric cancer To evaluate the diagnostic value of KAP1, TIMP1, STC2, TLN2, SRPX2, integrin beta 1 (ITGB1) and SPARC expression levels in the diagnosis of patients with gastric cancer, the area under the receiver operating characteristics (ROC) curves (AUC) value from ROC curve analysis was determined (Figure 1)
The AUC of TIMP1 was 0.767 ± 0.043 (P = 0.0001; 95% CI 0.682 to 0.851), the criterion value was 0.215 with a sensitivity of 61.5%, and the specificity was 83.0%
Summary
We examined preoperative kinesin II-associated protein (KAP1), TIMP metallopeptidase inhibitor 1 (TIMP1) and stanniocalcin 2 (STC2) expression levels in patients with gastric cancers to assess their clinical application for diagnosing and monitoring diseases. Patients who had undergone potentially curative surgery retain the risk of recurrence mainly because of tumor dissemination via the blood or lymphatic circulations. To improve the cure rates for patients with gastric cancer, the primary tumors must be detected at an early stage, and recurrent disease must be diagnosed while it is still minimal or clinically occult; micrometastases are currently. The proteins encoded by this gene family are natural inhibitors of the matrix metalloproteinases (MMPs), a group of peptidases involved in degradation of the extracellular matrix. TIMP1 has been shown to be overexpressed in both liver and peritoneal metastases from patients with colorectal adenocarcinoma [5] and malignant thyroid neoplasms [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
